SEL120-34A is a novel CDK8 inhibitor with potent activity against CDK8 (IC50 = 4.4 nM) and CDK19 (IC50 = 10.4 nM); it exhibits strong anti-tumor activity in hematologic malignancies, particularly in certain subtypes of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell lymphoma (MCL); it suppresses phosphorylation of STAT1 at S727 and STAT5 at S726, inhibits mitogen-induced immediate-early gene expression and interferon (IFN)-responsive genes, and modulates transcriptional programs associated with leukemia cell differentiation; in vivo, it demonstrates favorable pharmacodynamics, specifically alters interferon-responsive gene expression, inhibits proliferation of AML cell lines, spares normal hematopoietic function, and effectively suppresses tumor growth in xenograft models of AML and MCL upon oral administration.